Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 134

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

Wiman, K G·2010·Oncogene
DOI 10.1038/onc.2010.188
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2010.188

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 40

  1. Bartek J, Bartkova J, Lukas J . (2007). DNA damage signalling guards against activated oncogenes and tumor progression. Oncogene 26: 7773–7779. · DOI · Paper page
  2. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864–870. · DOI · Paper page
  3. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR . (2008). Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105: 10360–10365. · DOI · Paper page
  4. Bykov VJN, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J et al. (2005a). Restoration of tumor suppressor function to mutant p53 in human tumor cells by a maleimide analog. J Biol Chem 280: 30384–30391. · DOI · Paper page
  5. Bykov VJN, Lambert JMR, Hainaut P, Wiman KG . (2009). Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 8: 2509–2517. · DOI
  6. Chipuk JE, Maurer U, Green DR, Schuler M . (2003). Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4: 371–381. · DOI · Paper page
  7. Donehower LA, Lozano G . (2009). 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9: 831–841. · DOI · Paper page
  8. Foster BA, Coffey HA, Morin MJ, Rastinejad F . (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507–2510. · DOI · Paper page
  9. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C . (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874–1887. · DOI · Paper page
  10. Hainaut P, Wiman KG (eds). (2005). 25 Years of p53 Research. Springer: Dordrecht. ISBN 1-4020-2920-9. · DOI
  11. Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W et al. (2009). The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther 8: 2186–2193. · DOI
  12. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321–1328. · DOI · Paper page
  13. Joerger AC, Ang HC, Fersht AR . (2006). Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103: 15056–15061. · DOI · Paper page
  14. Joerger AC, Fersht AR . (2008). Structural biology of the tumor suppressor p53. Annu Rev Biochem 77: 557–582. · DOI · Paper page
  15. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B et al. (1999). Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 96: 9112–9117. · DOI · Paper page
  16. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670. · DOI · Paper page
  17. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. (2008). Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13: 454–463. · DOI · Paper page
  18. Lambert JMR, Moshfegh A, Hainaut P, Wiman KG, Bykov VJN . (2010). Mutant p53 reactivation by PRIMA-1MET induces multiple signalling pathways converging on apoptosis. Oncogene 29: 1329–1338. · DOI
  19. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577–590. · DOI · Paper page
  20. Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F et al. (2003). Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22: 3645–3654. · DOI · Paper page
  21. Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327–1341. · DOI · Paper page
  22. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG et al. (2004). Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 127: 285–291. · DOI · Paper page
  23. Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G et al. (2006). PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 132: 230–236. · DOI
  24. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P . (2002). Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 33: 181–188. · DOI
  25. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157–1167. · DOI · Paper page
  26. Peng Y, Li C, Chen L, Sebti S, Chen J . (2003). Rescue of mutant p53 transcription function by ellipticine. Oncogene 22: 4478–4487. · DOI
  27. Rippin TM, Bykov VJN, Freund SMV, Selivanova G, Wiman KG, Fersht AR . (2002). Characterization of the p53 rescue drug CP-31398 in vitro and in living cells. Oncogene 21: 2119–2129. · DOI · Paper page
  28. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD . (2001). Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. Pharmacol Exp Ther 297: 1067–1073. · DOI
  29. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG . (2008). PRIMA-1MET induces mitochondrial apoptosis via activation of caspase-2. Oncogene 27: 6571–6580. · DOI
  30. Sherr CJ, Weber JD . (2000). The ARF/p53 pathway. Curr Opin Genet Dev 10: 94–99. · DOI · Paper page
  31. Shi LM, Myers TG, Fan Y, O'Connor PM, Paull KD, Friend SH et al. (1998). Mining the national cancer institute anticancer drug discovery database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol 53: 241–251. · DOI
  32. Sigal A, Rotter V . (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788–6793.
  33. Soussi T, Wiman KG . (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303–312. · DOI · Paper page
  34. Vousden KH, Lu X . (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594–604. · DOI · Paper page
  35. Wang W, Takimoto R, Rastinejad F, El-Deiry WS . (2003). Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23: 2171–2181. · DOI · Paper page
  36. Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B et al. (2008). A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 15: 718–729. · DOI
  37. Wiman KG . (2006). Strategies for therapeutic targeting of the 53 pathway in cancer. Cell Death Differ 13: 921–926. · DOI
  38. Xu D, Qian W, Gruber A, Björkholm M, Chen Z, Zaid A et al. (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19: 5123–5133. · DOI · Paper page
  39. Zache N, Lambert JMR, Rökaeus N, Shen J, Hainaut P, Bergman J et al. (2008a). Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2: 70–80. · DOI · Paper page
  40. Zache N, Lambert JM, Wiman KG, Bykov VJ . (2008b). PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 30: 411–418.

Cited by

See all 134

Metadata

Authors
Wiman, K. G.
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2010-05-24
Volume
29
Issue
30
Pages
4245-4252
ISSN
  • 0950-9232
  • 1476-5594
DOI
10.1038/onc.2010.188
Cited by
134
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. https://app.cochat.ai/papers/10.1038/onc.2010.188
The paper
Wiman, K. G. (2010). Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene. https://doi.org/10.1038/onc.2010.188

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.